Cargando…

Risk stratification in hypertrophic cardiomyopathy

Detalles Bibliográficos
Autores principales:	Desai, Milind, Mentias, Amgad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461180/ https://www.ncbi.nlm.nih.gov/pubmed/30923259 http://dx.doi.org/10.18632/aging.101895

Ejemplares similares

Association of Septal Myectomy With Quality of Life in Patients With Left Ventricular Outflow Tract Obstruction From Hypertrophic Cardiomyopathy
por: Desai, Milind Y., et al.
Publicado: (2022)

Risk stratification in childhood hypertrophic cardiomyopathy
por: Norrish, Gabrielle, et al.
Publicado: (2018)

Arrhythmia Monitoring for Risk Stratification in Hypertrophic Cardiomyopathy
por: Du, Darson, et al.
Publicado: (2022)

Hypertrophic cardiomyopathy risk stratification based on clinical or dynamic electrophysiological features: two sides of the same coin
por: Sau, Arunashis, et al.
Publicado: (2023)

Arrhythmic Risk Stratification among Patients with Hypertrophic Cardiomyopathy
por: Santoro, Francesco, et al.
Publicado: (2023)

Hypertrophic Cardiomyopathy
por: Butt, Asra K., et al.
Publicado: (2023)

Hypertrophic cardiomyopathy: Sudden cardiac death risk stratification in adults
por: Jordà, Paloma, et al.
Publicado: (2018)

How Symptomatic Should a Hypertrophic Obstructive Cardiomyopathy Patient Be to Consider Alcohol Septal Ablation?
por: Jones, Brandon M., et al.
Publicado: (2017)

Risk stratification in cardiomyopathies (dilated, hypertrophic, and arrhythmogenic cardiomyopathy) by cardiac magnetic resonance imaging
por: Guglielmo, Marco, et al.
Publicado: (2021)

Orthostatic Blood Pressure Test for Risk Stratification in Patients with Hypertrophic Cardiomyopathy
por: Münch, Julia, et al.
Publicado: (2015)

The role of echocardiography for diagnosis and prognostic stratification in hypertrophic cardiomyopathy
por: Mandeş, Leonard, et al.
Publicado: (2020)

Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions
por: Dong, Tiffany, et al.
Publicado: (2023)

Left Ventricular Thrombus in Hypertrophic Cardiomyopathy
por: Hamada, Mareomi
Publicado: (2018)

Genetic and Molecular Mechanisms of Hypertrophic Cardiomyopathy
por: Chou, Chun, et al.
Publicado: (2023)

Risk Stratification in Hypertrophic Cardiomyopathy. Insights from Genetic Analysis and Cardiopulmonary Exercise Testing
por: Magrì, Damiano, et al.
Publicado: (2020)

Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy
por: Liu, Jie, et al.
Publicado: (2022)

The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy
por: Norrish, Gabrielle, et al.
Publicado: (2021)

Left Ventricular Mechanical Dispersion for the Better Risk Stratification of Patients With Hypertrophic Cardiomyopathy: Is It Possible?
por: Mohsenibadalabadi, Reza, et al.
Publicado: (2021)

Cardiac magnetic resonance as a risk re-stratification tool in apical hypertrophic cardiomyopathy
por: Larriva, Ana María, et al.
Publicado: (2023)

Risk assessment in hypertrophic cardiomyopathy: contemporary guidelines hampered by insufficient evidence
por: McKeown, Pascal P, et al.
Publicado: (2013)

Characteristics and Outcomes of Elderly Patients With Hypertrophic Cardiomyopathy
por: Alashi, Alaa, et al.
Publicado: (2021)

Sex, Survival, and Cardiomyopathy: Differences Between Men and Women With Hypertrophic Cardiomyopathy
por: Siontis, Konstantinos C., et al.
Publicado: (2019)

Hypertrophic Cardiomyopathy—Current Challenges and Future Perspectives
por: Monda, Emanuele, et al.
Publicado: (2023)

Are We Getting Closer to Risk Stratification in Left Ventricular Noncompaction Cardiomyopathy?
por: Jefferies, John L.
Publicado: (2018)

Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity
por: Bonaventura, Jiri, et al.
Publicado: (2023)

Prevention of Sudden Death in Hypertrophic Cardiomyopathy
por: Arteaga-Fernández, Edmundo, et al.
Publicado: (2018)

Risk stratification in cardiomyopathy
por: Sinagra, Gianfranco, et al.
Publicado: (2020)

Role of Implantable Cardioverter Defibrillators in the Treatment of Hypertrophic Cardiomyopathy
por: Ghosh, Joydeep, et al.
Publicado: (2005)

Pharmacological Strategies for Midventricular Obstruction in Patients with Hypertrophic Cardiomyopathy
por: Minami, Yuichiro, et al.
Publicado: (2018)

Late gadolinium enhancement is compatible with advanced age in hypertrophic cardiomyopathy: implications for risk stratification of sudden death
por: Chan, Raymond H, et al.
Publicado: (2012)

Late gadolinium enhancement cardiovascular magnetic resonance for sudden cardiac death risk stratification in hypertrophic cardiomyopathy
por: Ismail, Tevfik F, et al.
Publicado: (2013)

Incremental benefit of late gadolinium cardiac magnetic resonance imaging for risk stratification in patients with hypertrophic cardiomyopathy
por: Doesch, Christina, et al.
Publicado: (2017)

Validation of the 2020 AHA/ACC Risk Stratification for Sudden Cardiac Death in Chinese Patients With Hypertrophic Cardiomyopathy
por: Dong, Yan, et al.
Publicado: (2021)

Does papillary muscle free strain has predictive value in risk stratification of patients with hypertrophic cardiomyopathy?
por: Koyuncu, Atilla, et al.
Publicado: (2023)

Emergence of endocardium/epicardium flow gradient as novel risk biomarker in patients with hypertrophic cardiomyopathy
por: Schindler, Thomas H., et al.
Publicado: (2020)

Electrocardiograms for cardiomyopathy risk stratification in children with anthracycline exposure
por: Desai, Lajja, et al.
Publicado: (2019)

Role of the Extracellular Matrix in the Pathogenesis of Hypertrophic Cardiomyopathy
por: Marian, Ali J.
Publicado: (2019)

The consolidation of surgery for hypertrophic obstructive cardiomyopathy in Asia and the Pacific Rim
por: Quintana, Eduard, et al.
Publicado: (2021)

Myocardial Fibrosis in Hypertrophic Cardiomyopathy: What Remains to be Proven?
por: Sara, Leonardo
Publicado: (2019)

Septal Ablation in Obstructive Hypertrophic Cardiomyopathy (oHCM)
por: Almeida, Dirceu Rodrigues
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ks2t17l1hcm8t0fhkge3s7iv7n